Quick Answer
Journey Medical Corp reported Research And Development Expense of $480.0 thousand for the year ending 2025.
- Journey Medical Corp showed a decrease of -95.1% in Research And Development Expense from 2024 to 2025.
- This data is from Journey Medical Corp's annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $29.0 thousand | Q3 2021: $718.0 thousand | Q1 2022: $1.27 million | Q2 2022: $2.61 million | Q3 2022: $2.81 million | Q1 2023: $2.03 million | Q2 2023: $1.77 million | Q3 2023: $2.23 million | Q1 2024: $7.88 million | Q2 2024: $913.0 thousand | Q3 2024: $842.0 thousand | Q1 2025: $39.0 thousand | Q3 2025: $287.0 thousand.
- Over the full 5 years of available data (2021 to 2025), Journey Medical Corp's Research And Development Expense has declined by 82.5%.
- Historical annual values: Fiscal year 2025: $480.0 thousand | Fiscal year 2024: $9.86 million | Fiscal year 2023: $7.54 million | Fiscal year 2022: $10.94 million | Fiscal year 2021: $2.74 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: